|
Targacept initiates two anti-inflammatory drug studies
Pharmaceutical Business Review Targacept has initiated two separate Phase II studies of its product candidate TC-6987 in disorders characterised by inflammation, in asthma and Type II … Targacept to begin Phase 2 trials of drug that could treat asthma, diabetes Targacept starts new trial for diabetes drug TARGACEPT : Announces Initiation of Phase 2 Studies of TC-6987 in Asthma and … |
View full post on asthma – Google News